Shanghai Biomabs Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Remicade · Oncology

Phase 3 pipeline

• CMAB008 · Oncology
  CMAB008 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
• CMAB807 Injection · Oncology
  CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses.

Phase 1 pipeline

• CMAB818

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Biomabs Pharmaceutical Co., Ltd. portfolio CI brief
• Shanghai Biomabs Pharmaceutical Co., Ltd. pipeline updates RSS